Comparative Pharmacology
Head-to-head clinical analysis: DELFLEX W DEXTROSE 4 25 LOW MAGNESIUM IN PLASTIC CONTAINER versus DELFLEX LM W DEXTROSE 3 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DELFLEX W DEXTROSE 4 25 LOW MAGNESIUM IN PLASTIC CONTAINER versus DELFLEX LM W DEXTROSE 3 5 IN PLASTIC CONTAINER.
DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM IN PLASTIC CONTAINER vs DELFLEX-LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Delflex with Dextrose 4.25% Low Magnesium is a peritoneal dialysis solution that uses dextrose as an osmotic agent to create a concentration gradient across the peritoneal membrane, allowing for the removal of uremic toxins and excess fluid via ultrafiltration. The low magnesium concentration (0.25 mEq/L) helps prevent hypermagnesemia in patients with renal failure.
DELFLEX-LM W/ DEXTROSE 3.5% is a peritoneal dialysis solution. Its mechanism of action involves osmotic ultrafiltration across the peritoneal membrane, facilitated by high dextrose concentration, to remove excess fluid and waste products (e.g., urea, creatinine) from the blood in patients with end-stage renal disease.
Continuous ambulatory peritoneal dialysis (CAPD)Continuous cycling peritoneal dialysis (CCPD)
FDA-approved for use as a peritoneal dialysis solution in continuous ambulatory peritoneal dialysis (CAPD) and automated peritoneal dialysis (APD) for patients with acute or chronic renal failure.Off-label: management of fluid overload in patients with heart failure resistant to diuretics (rare).
Intraperitoneal administration: 2 L per exchange, 4 exchanges daily. Dextrose concentration (1.5%, 2.5%, or 4.25%) determined by ultrafiltration needs. Low magnesium formulation selected based on serum magnesium levels.
Intraperitoneal: 1.5% to 4.25% dextrose solution; 2 to 2.5 L per exchange, typically 4 exchanges per 24 hours; dwell time 4 to 6 hours.
None Documented
None Documented
Intraperitoneal dextrose: absorption half-life ~1.5-2 hours; elimination of absorbed glucose follows endogenous glucose kinetics (t1/2 ~1-2 hours). Clinical note: Continuous dwell results in steady-state concentrations.
Not applicable for dextrose; for lactate/bicarbonate buffer components, half-life is approximately 2-4 hours in peritoneal cavity with systemic absorption minimal. Clinical context: continuous dialysis maintains steady-state.
Dextrose is metabolized via glycolysis and the citric acid cycle; magnesium is excreted renally and undergoes reabsorption in the kidneys; other electrolytes are regulated by renal function. No specific enzyme induction or inhibition noted.
Dextrose is metabolized via glycolysis and the citric acid cycle to carbon dioxide and water, with some absorption from the peritoneal cavity. Lactate (from the buffer) is metabolized primarily in the liver to bicarbonate.
Primarily renal (peritoneal clearance): ~60-80% of glucose absorbed is metabolized; dextrose metabolites (CO2, water) excreted via lungs and kidneys. Magnesium and other electrolytes are removed via peritoneal dialysis; net elimination varies with dialysis prescription.
Peritoneal dialysis: Removal of waste products (urea, creatinine) via peritoneal membrane; approximately 60-80% of urea is removed during a 4-6 hour dwell. Biliary/fecal: minimal (<5%). Renal: negligible as drug is primarily used in renal failure.
Dextrose: negligible binding. Magnesium: ~30% bound to albumin; Low Magnesium formulation minimizes magnesium load.
Dextrose: negligible (<5%); electrolytes: negligible. Peritoneal dialysis solutions per se do not have significant protein binding.
Dextrose: Vd ~0.2-0.3 L/kg (total body water). Magnesium: Vd ~0.5-0.7 L/kg. Clinical meaning: Distributes into extracellular fluid; low Vd reflects limited tissue distribution.
Dextrose distributes in total body water (approximately 0.6 L/kg); for dialysate, distribution into peritoneal cavity volume is 2-3 L.
Intraperitoneal: dextrose absorption is 60-80% over a dwell; systemically bioavailable as absorbed glucose. Not applicable for IV or other routes.
Intraperitoneal: 100% for local effects; systemic absorption of glucose occurs (approximately 60-80% of glucose load) via peritoneal capillaries.
No dose adjustment for renal impairment; drug is administered intraperitoneally for peritoneal dialysis. Monitor serum electrolytes and ultrafiltration.
Deliver via peritoneal dialysis; no dose adjustment necessary as drug is administered intraperitoneally for renal replacement therapy.
No specific adjustment; caution in hepatic impairment due to risk of lactate metabolism impairment with dextrose. Monitor serum lactate and electrolytes.
No specific dose adjustment; monitor for signs of hepatic encephalopathy or fluid overload in severe hepatic impairment.
Weight-based: 30-40 mL/kg per exchange, 4-5 exchanges daily. Adjust dextrose concentration based on ultrafiltration target. Low magnesium product used if hypermagnesemia risk.
Intraperitoneal: 20 to 40 mL/kg per exchange (typical fill volume 800-1100 mL/m2), 4 to 5 exchanges per 24 hours; dwell time 2 to 6 hours per exchange.
No specific dose adjustment; monitor fluid status, electrolytes, and ultrafiltration volume closely due to increased risk of volume overload and electrolyte disturbances.
No specific dose adjustment; monitor for fluid and electrolyte balance, and adjust dextrose concentration based on ultrafiltration needs and glucose tolerance.
None
None.
["Not for intravenous use","Risk of peritonitis","Electrolyte imbalance (hypokalemia, hypomagnesemia, hypocalcemia)","Fluid overload or dehydration","Hyperglycemia, especially in diabetic patients","Abdominal wall hernias","Ileus or mechanical obstruction","Encapsulating peritoneal sclerosis (rare)"]
Risk of peritonitis, abdominal pain, electrolyte disturbances (e.g., hyperglycemia, hypernatremia, hypokalemia), fluid overload, and metabolic acidosis. Use with caution in patients with severe hyponatremia, hypokalemia, or impaired liver function.
["Pre-existing severe hypokalemia","Hypercalcemia","Severe hyperglycemia uncorrected","Significant abdominal adhesions or fibrosis","Pre-existing peritoneal diaphragmatic defects","History of severe pancreatitis or diverticulitis","Inability to perform dialysis exchanges safely"]
Hypersensitivity to any component; pre-existing hyperglycemia; severe hyponatremia; hypokalemia; hyperlactatemia; or conditions with increased peritoneal permeability (e.g., peritonitis, severe burns).
Data Pending Review
Data Pending Review
No direct food interactions with the solution itself, but dietary management is critical. Magnesium-restricted diet advised if serum magnesium is elevated; avoid high-magnesium foods like nuts, seeds, legumes, whole grains, chocolate, bananas, and dark leafy greens. Dextrose content may affect glycemic control; diabetic patients should monitor carbohydrate intake and adjust insulin as needed. Potassium and phosphorus restrictions may also apply based on individual lab values.
Dietary restrictions typically include low sodium, low potassium, and low phosphorus intake to manage fluid and electrolyte balance. Avoid high-sugar foods if hyperglycemia develops. Consult a renal dietitian for individualized meal planning.
Delflex with Dextrose 4.25% Low Magnesium is a peritoneal dialysis solution. There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies have not been conducted with this solution. In general, peritoneal dialysis may cause electrolyte disturbances and fluid shifts that could affect fetal well-being. Hyperglycemia from dextrose absorption may pose risks during organogenesis (first trimester) and later trimesters. Use only if clearly needed and monitor maternal glucose and electrolytes closely.
No evidence of teratogenicity in animal studies; human data are lacking. However, in case of severe maternal electrolyte disturbances or infection, potential indirect fetal risks may arise. Generally considered low risk if administered appropriately.
It is not known whether Delflex components are excreted in human milk. Dextrose is a normal constituent of milk. Calcium, magnesium, and sodium are present in milk and the additional amounts from dialysis are likely negligible. However, due to potential for systemic absorption of dextrose and electrolyte shifts, caution is advised. No M/P ratio is available.
Excretion into breast milk is expected to be minimal due to high molecular weight, but specific M/P ratio not reported. Compatible with breastfeeding if maternal therapy is necessary; caution due to possible high glucose load in neonates.
Dosing of peritoneal dialysis solution (volume, dwell time, number of exchanges) should be individualized based on maternal renal function, electrolyte status, and glycemic control. Pregnancy may require increased dialysis dose due to increased metabolic demands and volume of distribution. Monitor blood glucose closely as dextrose absorption can cause hyperglycemia; insulin adjustment may be necessary. No specific dose adjustment of the solution is defined; clinical judgment and frequent monitoring are required.
Standard dosing may be used; however, pregnancy-induced hypervolemia and increased glomerular filtration rate may require adjustment of exchange volumes and dextrose concentration to maintain electrolyte and glucose homeostasis. Close monitoring of maternal weight, blood pressure, and serum chemistries is recommended.
Category C
Category C
DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM is a peritoneal dialysis solution indicated for patients with end-stage renal disease (ESRD) to remove waste products and excess fluid via the peritoneal membrane. The low magnesium formulation (0.5 mEq/L) is specifically designed for patients at risk of hypermagnesemia, such as those with impaired renal function or on magnesium-containing medications. Monitor serum magnesium levels regularly; hypomagnesemia is also possible if dietary intake is insufficient. The 4.25% dextrose concentration provides the highest ultrafiltration capacity among standard solutions, making it suitable for fluid overload states. Use with caution in patients with severe hyperglycemia or glucose intolerance, as the dextrose load may elevate blood glucose. Ensure sterile technique during bag exchange to prevent peritonitis.
This is a peritoneal dialysis solution containing 3.5% dextrose. Use the lowest dextrose concentration necessary for adequate ultrafiltration to avoid hyperglycemia and metabolic complications. Warm the solution to body temperature before administration to reduce patient discomfort. Monitor serum electrolytes, glucose, and urea regularly. Do not use if solution is discolored or contains particulates.
Wash hands thoroughly before handling the dialysis bag or catheter site.Inspect the solution bag for cloudiness, discoloration, or leaks; do not use if present.Use only as directed by your healthcare provider about the number and duration of exchanges.Report any signs of infection such as redness, swelling, or drainage at the catheter site, or abdominal pain, fever, or nausea.Monitor your blood glucose levels if you have diabetes, as the dextrose in the solution may raise blood sugar.Follow a kidney-friendly diet as recommended, which may include limiting certain foods high in magnesium (e.g., nuts, seeds, leafy greens) if your magnesium levels are high.Do not reuse the dialysis bag or tubing; dispose as instructed.Keep a log of your daily weight and report any rapid weight gain or persistent edema.Avoid vigorous exercise that could dislodge the catheter.Seek immediate medical attention if you experience shortness of breath, chest pain, or severe abdominal pain.
Store the solution at room temperature and protect from light.Warm the bag to body temperature before use for comfort.Inspect the solution for clarity and discard if cloudy or containing particles.Follow aseptic technique to prevent peritonitis.Report any signs of infection (fever, abdominal pain, cloudy effluent) immediately.